{
  "id": 28300,
  "title": "Optimising scale-up of injectable lenacapavir for HIV pre-exposure prophylaxis in South Africa: A modelling study and economic evaluation",
  "url": "https://urgent.news/2026/07/21/optimising-scale-up-of-injectable-lenacapavir-for-hiv-pre-exposure",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-07-21T14:00:00.000Z",
  "source": {
    "name": "PLOS Medicine",
    "slug": "plos-medicine",
    "url": "https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004882"
  },
  "original_language": "en",
  "account": null,
  "summary": "by Lise Jamieson, Leigh F. Johnson, Jeffrey W. Imai-Eaton, Hasina Subedar, Linda-Gail Bekker, Gesine Meyer-Rath Background South Africa accounts for 20% of global HIV infections. Six-monthly injectable lenacapavir (LEN) for HIV pre-exposure prophylaxis (PrEP) has superior efficacy to oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), and similar efficacy to 2-monthly injectable…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}